The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1515
Drug Interaction: Clopidogrel and PPIs
The full article is available to subscribers Subscriber Login   

The antiplatelet drug clopidogrel (Plavix, and others) reduces major cardiovascular events, but can cause bleeding. Proton pump inhibitors (PPIs) are often used with clopidogrel to prevent gastrointestinal bleeding, however, some evidence suggests that PPIs may interfere with the activation of clopidogrel and diminish its antiplatelet effect.1 FDA-approved labeling recommends avoiding concurrent use of the PPIs omeprazole and esomeprazole with clopidogrel.

POSSIBLE MECHANISM — Clopidogrel is a prodrug; the CYP2C19 isozyme appears to be mainly responsible for its bioactivation.2 Concurrent use of clopidogrel and drugs that inhibit CYP2C19 could inhibit conversion of clopidogrel to its active form. Among the PPIs, omeprazole and esomeprazole appear to be the strongest inhibitors of CYP2C19 and pantoprazole appears to be the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drug Interaction: Clopidogrel and PPIs
Article code: 1515f
 Electronic, downloadable article - $25